Scientific Resources
Lead. Live. Boldly.
Featured Publication
2026 | ECNP
LB-102 effect on dopamine D2 autoreceptors: Results from a preclinical study evaluating dopamine efflux in rat nucleus accumbens using microdialysis
Source
Title
2026
Article
JAMA Psychiatry
Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial
2026
Oral Presentation
SIRS
LB-102 for Acute Schizophrenia in Adults Results From the Phase 2 NOVA1 Clinical Trial, With a Focus on PANSS Marder Factor Scores
2026
Poster Presentation
SIRS
LB-102 for cognition in patients with schizophrenia: an exploratory post hoc analysis from a randomised, double-blind, placebo-controlled phase 2 study
2025
Poster Presentation
ECNP
LB-102 for acute schizophrenia in adults: efficacy and safety from a large phase 2 clinical trial
2025
Poster Presentation
ECNP
LB-102 for acute schizophrenia in adults: Results from the phase 2 clinical trial (NOVA1) with a focus on Negative Symptoms
2025
Poster Presentation
ECNP
LB-102 for cognitive impairment in schizophrenia: exploratory post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
2025
Oral Presentation
ASCP
Oral, Once-Daily LB-102: Recent Positive Results From a Phase 2 Study in Patients With Acute Schizophrenia
2025
Poster Presentation
SIRS
LB-102 for Acute Schizophrenia in Adults: Efficacy and Safety From a Large Phase 2 Clinical Trial
2024
Article
Nature Neuropsychopharmacology
PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement
2024
Poster Presentation
ASCP
LB-102, a novel benzamide for the treatment of schizophrenia: safety and dopamine receptor occupancy data from two clinical studies
2022
Article
Springer Nature Psychopharmacology
A randomized, double‑blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB‑102
2021
Poster Presentation
ACNP
PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor engagement
2021
Poster Presentation
ECNP
LB-102 displays superior dopamine receptor occupancy compared to amisulpride in mouse and human PET studies
2020
Poster Presentation
ECNP
Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2/5-HT7 antagonist, in healthy volunteers
2019
Poster Presentation
ECNP
Building a translational bridge from animals to man for clinical candidate LB-102, a next-generation benzamide antipsychotic
2019
Article
ACS Omega
Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5‑HT7
2018
Poster Presentation
SOBP
Establishing a PK-PD-E Relationship for Clinical Candidate LB-102, a Next-Generation Benzamide Antipsychotic
2018
Poster Presentation
ECNP
LB-102, Potential Schizophrenia Treatment, Displays Polypharmacology as a Racemate—S Enantiomer Binds D2 Receptors and R Binds 5-HT7Receptor
2017
Poster Presentation
ECNP
Pre-clinical Evaluation of Two Novel Benzamides LB-102 and 103 for the Treatment of Schizophrenia
Source
Title
Amisulpride in Schizophrenia
2019
Article
Lancet
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
2008
Article
Lancet
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
Amisulpride in Depression
2002
Article
Int Clin Psychopharmacol
Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study
2001
Article
Int Clin Psychopharmacol
Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study
1999
Article
Neuropsychobiology
Amisulpride versus amineptine and placebo for the treatment of dysthymia
Amisulpride and Negative Symptoms of Schizophrenia
2018
Article
The British Journal of Psychiatry
Treatment of Negative Symptoms in Schizophrenia with Amisulpride
1999
Article
Am J Psychiatry
Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group
1997
Article
The British Journal of Psychiatry
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
Amisulpride and Cognition
2014
Article
Ind Psychiatry J
Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study
Amisulpride in Alzheimer's Disease
2006
Article
Neuropsychobiology
Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study
2006
Article
Acta Neurologica Scandinavica
Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer’s disease
Amisulpride in Elderly
2018
Article
Lancet Psychiatry
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial
2014
Article
J Clin Psychopharmacol
Amisulpride for older patients with long-standing schizophrenia
2009
Article
Int J Geriatr Psychiatry
Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis
Amisulpride in Mechanism of Action
2008
Article
Pharmacopsychiatry
Striatal D2 / D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study
1997
Article
Int Clin Psychopharmacol
Amisulpride: from animal pharmacology to therapeutic action
Source
Title
Bipolar Depression
2022
Article
J Affect Disord
A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression
2017
Article
J Clin Psychopharmacol
Guarding the Gate – Remote Structured Assessments to Enhance Enrollment Precision in Depression Trials
2013
Article
Harvard Review of Psychiatry
Massachusetts General Hospital SAFER Criteria for Clinical Trials and Research
2005
Article
Clin Psychol Rev
Distinctions between bipolar and unipolar depression
2003
Article
Neuropsychopharmacology